基于食品经济学的方法揭示了多在炎症性肠病中的潜在保护作用
Giovanni Pratelli1, Bartolo Tamburini2,3, Daniela Carlisi2
1Department of Physics and Chemistry (DiFC) Emilio Segrè, University of Palermo, 90128 Palermo, Italy.
International journal of molecular sciences
|October 14, 2023
概括
饮食中的多可能有助于通过对抗肠道失调和氧化应激来控制炎症性肠病 (IBD). 食品经济学和先进的多技术为IBD治疗提供了新的治疗途径.
科学领域:
- 胃肠病学 胃肠病学
- 营养科学 营养科学
- 分子生物学分子生物学
背景情况:
- 炎症性肠病 (IBD) 是一种慢性胃肠道疾病,与遗传,微生物和环境因素有关.
- IBD的特点是肠道失调,有益细菌减少,致病物种增加,导致炎症和氧化应激.
- 由反应性氧物种 (ROS) 失衡引起的氧化应激会损害肠道上皮,并增加IBD中的透性.
研究的目的:
- 探索饮食中的多在治疗炎症性肠病 (IBD) 中的治疗潜力.
- 研究食品经济学和先进的多技术如何为IBD治疗策略提供信息.
- 突出自然抗氧化剂作为IBD治疗的潜在候选者.
主要方法:
- 对IBD病变发生,肠道微生物群和氧化应激现有证据的审查.
- 分析饮食中的多作为胃肠道中的天然抗氧化剂的作用.
- 探索食品经济学方法和新技术,以提高多的疗效.
主要成果:
- 饮食中的多可以维持氧化还原平衡,抵消肠道失调和炎症.
- 聚醇显示在预防肠道上皮损伤和减少ROS积累方面具有潜力.
- 先进的技术可以增强抗氧化特性和多的治疗应用.
结论:
- 饮食中的多醇代表了一种有前途的天然抗氧化剂策略,用于控制IBD.
- 食品经济学和创新的多提供/修改技术对于推进IBD治疗至关重要.
- 整合天然抗氧化剂,如多,为IBD治疗提供了一个全面的视角.
更多相关视频
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
339
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
339
Inflammatory Bowel Disease IV: Pharmacological Management
135
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
135
Inflammatory Bowel Disease I: Ulcerative Colitis
196
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
196
Drugs for Treatment of Ulcerative Colitis in IBD
152
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
152
Inflammatory Bowel Disease II: Crohn's Disease
264
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
264
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
462
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
462


